Related Experiment Videos
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma
L H Wong1, K G Krauer, I Hatzinisiriou
1Department of Biochemistry and Molecular Biology, Monash University, Wellington Road, Clayton, Victoria 3168, Australia.
Abstract:
The mechanism of IFN resistance was examined in three long-term cell lines, SK-MEL-28, SK-MEL-3, and MM96, exhibiting significant variation in responsiveness to the antiproliferative and antiviral effects of type I IFNs. The JAK-STAT components involved in IFN signal transduction were analyzed in detail. After exposure to IFN, activation of the IFN type I receptor-linked tyrosine kinases, JAK-1 and TYK-2, was detected at similar levels in both IFN-sensitive and IFN-resistant cell types, indicating that IFN resistance did not result from a deficiency in signaling at the level of receptor-associated kinase activation. However, analysis of ISGF3 transcription factor components, STAT1, STAT2, and p48-ISGF3gamma, revealed that their expression and activation correlated with cellular IFN responsiveness. The analysis was extended to also include IFN-sensitive primary melanocytes, three additional IFN-resistant melanoma cell lines, and seven cell cultures recently established from melanoma patient biopsies. It was consistently observed that the most marked difference in ISGF3 was a lack of STAT1 in the resistant versus the sensitive cells. Transfection of the IFN-resistant MM96 cell line to express increased levels of STAT1 protein partially restored IFN responsiveness in an antiviral assay. We conclude that a defect in the level of STAT1 and possibly all three ISGF3 components in IFN-resistant human melanoma cells may be a general phenomenon responsible for reduced cellular responsiveness of melanomas to IFNs.
Insights
IFN resistance in melanoma is linked to lower levels of STAT1, a key protein in the ISGF3 complex. Restoring STAT1 partially restored sensitivity to Interferon (IFN) in resistant cells.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Type I interferons (IFNs) have antiproliferative and antiviral effects.
- Melanoma cell lines display varied responsiveness to type I IFNs.
- Understanding IFN resistance mechanisms is crucial for cancer therapy.
Purpose of the Study:
- To investigate the molecular mechanisms underlying type I IFN resistance in human melanoma cells.
- To identify specific components of the JAK-STAT signaling pathway involved in IFN resistance.
Main Methods:
- Analysis of JAK-STAT pathway components in IFN-sensitive and IFN-resistant melanoma cell lines.
- Assessing expression and activation of transcription factors STAT1, STAT2, and p48-ISGF3gamma.
- Functional validation through STAT1 re-expression in resistant cells.
Main Results:
- IFN receptor-associated kinase activation (JAK-1, TYK-2) was similar in sensitive and resistant cells.
- Expression and activation of ISGF3 components correlated with cellular IFN responsiveness.
- A significant lack of STAT1 was consistently observed in IFN-resistant melanoma cells compared to sensitive cells.
- Restoring STAT1 levels in resistant cells partially restored IFN sensitivity.
Conclusions:
- IFN resistance in human melanoma is associated with defects in STAT1 and potentially other ISGF3 components.
- Reduced STAT1 levels are a key factor contributing to melanoma's diminished responsiveness to IFNs.
- Targeting STAT1 may represent a therapeutic strategy to overcome IFN resistance in melanoma.